Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application for Zuranolone to the FDA in 2022
The FDA will review zuranolone for the treatment of depression in the first half of 2022.
Recruiting New Mothers with Postpartum Depression for the Skylark Study
In 2019, brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression. The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]
More Data on the Neuroactive Steroid Zuranolone for Postpartum Depression
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]
Development of Zuranolone (SAGE 217) for PPD Will Move Forward
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
Don’t Forget About Brexanolone’s Little Sister: Zuranolone
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
Zulresso: Hope and Lingering Questions
Publish date: September 10, 2019 By Lee S. Cohen, MD The last decade has brought increasing awareness of the need to effectively screen for postpartum depression, with a majority of states across the country now having [...]
Oral Allopregnanolone Analogue for Postpartum Depression Treatment
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of [...]
![By Vera Kratochvil [Public domain], via Wikimedia Commons](https://womensmentalhealth.org/wp-content/uploads/2015/06/Mother_Kissing_Baby-320x202.jpg)
More Data on SAGE-547, A Novel Treatment for Severe Postpartum Depression
About a year ago, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. SAGE-547 is a new drug, an allosteric modulator of GABAA receptors, which was initially [...]